Comparative Study of Three NNRTI-Sparing HAART Regimens
The ARDENT Study: Atazanavir, Raltegravir, or Darunavir With Emtricitabine/Tenofovir for Naive Treatment
Sponsor: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
A PHASE3 clinical study on HIV Infection, this trial is completed. The trial is conducted by Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections and has accumulated 9 data snapshots since 2009. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jun 2024 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2022 — Jun 2024 [monthly]
Completed PHASE3
▶ Show 4 earlier versions
-
Jan 2021 — Jun 2022 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
May 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
- Bristol-Myers Squibb
- Gilead Sciences
- Merck Sharp & Dohme LLC
- National Institute of Allergy and Infectious Diseases (NIAID)
- Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA
For direct contact, visit the study record on ClinicalTrials.gov .